Group A was obese associated NAFLD with abnormal liver test ( n =60),group B was obese without NAFLD( n =16), group C was obese associated NAFLD( n =12),group D was obese with both ALT and AST elevation ( n =19).
英
美
- A組為肥胖伴NAFLD和肝損傷組 (60例 ) ,B組為無(wú)脂肪肝肥胖組 (16例 ) ,C組為肥胖伴NAFLD組 (12例 ) ,D組為丙氨酸轉氨酶 (ALT)和天冬氨酸轉氨酶 (AST)均升高組 (19例 ) ,其中A組給予奧利司他 12 0mg ,每日 3次 ,結合低熱卡飲食 ,共治療 2 4周。
